

PRIOR AUTHORIZATION POLICY

POLICY: Complement Inhibitors – Soliris Prior Authorization Policy

- Soliris® (eculizumab intravenous infusion – Alexion)

REVIEW DATE: 05/04/2022

OVERVIEW

Soliris, a complement C5 inhibitor, is indicated for the following uses:¹

- **Atypical hemolytic uremic syndrome (aHUS)**, to inhibit complement-mediated thrombotic microangiopathy.
- **Generalized myasthenia gravis (gMG)**, in adults who are anti-acetylcholine receptor (AChR) antibody positive.
- **Neuromyelitis optica spectrum disorder (NMOSD)**, in adults who are anti-aquaporin-4 (AQP4) antibody positive.
- **Paroxysmal nocturnal hemoglobinuria (PNH)**, to reduce hemolysis.

Soliris is not indicated for the treatment of patients with Shiga toxin *E. coli* related hemolytic uremic syndrome. The safety and effectiveness of Soliris for the treatment of PNH, gMG, and NMOSD in pediatric patients have not been established. The safety and effectiveness of Soliris in pediatric patients for aHUS is supported by evidence from four adequate and well-controlled clinical studies assessing the safety and effectiveness of Soliris for the treatment of aHUS.

Disease Overview

Myasthenia gravis (MG) is a chronic autoimmune neuromuscular disease that causes weakness in the skeletal muscles, which are responsible for breathing and moving parts of the body, including the arms and legs.⁴ The hallmark of myasthenia gravis is muscle weakness that worsens after periods of activity and improves after periods of rest. Certain muscles such as those that control eye and eyelid movement, facial expression, chewing, talking, and swallowing are often involved in the disorder; however, the muscles that control breathing and neck and limb movements may also be affected. Acquired MG results from the binding of autoantibodies to components of the neuromuscular junction, most commonly the acetylcholine receptor.⁵

NMOSD is a rare, relapsing, autoimmune disorder of the brain and spinal cord with optic neuritis and/or myelitis as predominate characteristic symptoms.⁶ NMOSD often causes significant, permanent damage to vision and/or spinal cord function causing blindness or impaired mobility.⁷ Patients may experience pain, paralysis, loss of bowel and bladder control, loss of visual acuity, uncontrolled motor functions, and complications can cause death. Uplizna™ (inebilizumab-cdon intravenous infusion) and Enspryng™ (satralizumab-mwge subcutaneous injection) are two other FDA-approved medications for treatment of NMOSD in adults who are anti-AQP4 antibody-positive.^{8,9} For acute attacks, typical treatment is high-dose intravenous corticosteroids.^{10,11} Plasma exchange may be effective in patients who suffer acute severe attacks that do not response to intravenous corticosteroids. For long-term control of the disease a variety of immunosuppressive drugs are utilized as first-line therapy. While all are considered off-label use, corticosteroids, azathioprine, mycophenolate mofetil, and rituximab are treatments prescribed as preventative therapy.

PNH is a rare disorder involving bone marrow failure that manifests with hemolytic anemia, thrombosis, and peripheral blood cytopenias.¹² Due to the absence of two glycosylphosphatidylinositol (GPI)-anchored

05/04/2022

© 2022. All Rights Reserved.

This document is confidential and proprietary. Unauthorized use and distribution are prohibited.

proteins, CD55 and CD59, uncontrolled complement activation leads to hemolysis and other PNH manifestations.¹³ GPI anchor protein deficiency is often due to mutations in phosphatidylinositol glycan class A (PIGA), a gene involved in the first step of GPI anchor biosynthesis. PNH is a clinical diagnosis that should be confirmed with peripheral blood flow cytometry to detect the absence or severe deficiency of GPI-anchored proteins on at least two lineages.¹⁴ Prior to the availability of Soliris, there was no specific therapy for PNH with only supportive management in terms of the cytopenias and control of thrombotic risk. Supportive measures used include platelet transfusion, immune suppressive therapy for patients with bone marrow failure, use of erythropoietin for anemias, and aggressive anticoagulation. Soliris is the treatment of choice for patients with severe manifestations of PNH. Bone marrow transplantation is the only cure for PNH but should be reserved for patients with a suboptimal response to Soliris. Other agents indicated for the management of PNH in adults include Empaveli™ (pegcetacoplan subcutaneous infusion), a complement C3 inhibitor, and Ultomiris® (ravulizumab intravenous infusion), a complement C5 inhibitor.^{15,16}

Guidelines

An international consensus guidance for the management of MG was published in 2016.⁵ The guidelines recommend pyridostigmine for the initial treatment in most patients with MG. The ability to discontinue pyridostigmine can indicate that the patient has met treatment goals and may guide the tapering of other therapies. Corticosteroids or immunosuppressant therapy should be used in all patients with MG who have not met treatment goals after an adequate trial of pyridostigmine. Nonsteroidal immunosuppressant agents include azathioprine, cyclosporine, mycophenolate mofetil, methotrexate, and tacrolimus. It is usually necessary to maintain some immunosuppression for many years, sometimes for life. Plasma exchange and intravenous immunoglobulin can be used as short-term treatments in certain patients. A 2020 update to these guidelines provides new recommendations for methotrexate, rituximab, and Soliris.¹⁷ All recommendations should be considered extensions or additions to recommendations made in the initial international consensus guidance. Oral methotrexate may be considered as a steroid-sparing agent in patients with generalized MG who have not tolerated or responded to steroid-sparing agents. Rituximab should be considered as an early therapeutic option in patients with muscle specific kinase antibody positive MG who have an unsatisfactory response to initial immunotherapy. Soliris should be considered in the treatment of severe, refractory, anti-acetylcholine receptor antibody positive generalized MG.

POLICY STATEMENT

Prior Authorization is recommended for prescription benefit coverage of Soliris. All approvals are provided for the duration noted below. In cases where the approval is authorized in months, 1 month is equal to 30 days. Because of the specialized skills required for evaluation and diagnosis of patients treated with Soliris as well as the monitoring required for adverse events and long-term efficacy, approval requires Soliris to be prescribed by or in consultation with a physician who specializes in the condition being treated.

Automation: None.

RECOMMENDED AUTHORIZATION CRITERIA

Coverage of Soliris is recommended in those who meet one of the following criteria:

FDA-Approved Indications

- 1. Atypical Hemolytic Uremic Syndrome.** Approve for 1 year if the patient meets the following criteria (A and B):
 - A)** Patient does not have Shiga toxin *E. coli* related hemolytic uremic syndrome; AND

- B) The medication is being prescribed by or in consultation with a nephrologist.
2. **Generalized Myasthenia Gravis.** Approve if the patient meets ONE of the following criteria (A or B):
- A) **Initial therapy.** Approve for 6 months if the patient meets the following criteria (i, ii, iii, iv, v, vi, and vii):
- i. Patient is ≥ 18 years of age; AND
 - ii. Patient has confirmed anti-acetylcholine receptor antibody positive generalized myasthenia gravis; AND
 - iii. Patient meets both of the following (a and b):
 - a) Myasthenia Gravis Foundation of America classification of II to IV; AND
 - b) Myasthenia Gravis Activities of Daily Living (MG-ADL) score of ≥ 5 ; AND
 - iv. Patient meets one of the following (a or b):
 - a) Patient received or is currently receiving pyridostigmine; OR
 - b) Patient has had inadequate efficacy, a contraindication, or significant intolerance to pyridostigmine; AND
 - v. Patient meets one of the following (a or b):
 - a) Patient received or is currently receiving two different immunosuppressant therapies for ≥ 1 year; OR
 - b) Patient had inadequate efficacy, a contraindication, or significant intolerance to two different immunosuppressant therapies; AND
Note: Examples of immunosuppressant therapies tried include azathioprine, cyclosporine, mycophenolate mofetil, methotrexate, tacrolimus, and cyclophosphamide.
 - vi. Patient has evidence of unresolved symptoms of generalized myasthenia gravis, such as difficulty swallowing, difficulty breathing, or a functional disability resulting in the discontinuation of physical activity (e.g., double vision, talking, impairment of mobility); AND
 - vii. The medication is being prescribed by or in consultation with a neurologist.
- B) **Patient is Currently Receiving Soliris.** Approve for 1 year if the patient meets the following (i, ii, and iii):
- i. Patient is ≥ 18 years of age; AND
 - ii. Patient is continuing to derive benefit from Soliris, according to the prescriber; AND
Note: Examples of derived benefit include reductions in exacerbations of myasthenia gravis; improvements in speech, swallowing, mobility, and respiratory function.
 - iii. The medication is being prescribed by or in consultation with a neurologist.
3. **Neuromyelitis Optica Spectrum Disorder.** Approve if the patient meets ONE of the following criteria (A or B):
- A) **Initial Therapy.** Approve for 1 year if the patient meets the following criteria (i, ii, iii, iv, and v):
- i. Patient is ≥ 18 years of age; AND
 - ii. Neuromyelitis optica spectrum disorder diagnosis was confirmed by a positive blood serum test for anti-aquaporin-4 antibody; AND
 - iii. Patient is currently receiving or has previously tried two of the following systemic therapies (a, b, c, or d):
 - a) Azathioprine; OR
 - b) Corticosteroid; OR
 - c) Mycophenolate mofetil; OR
 - d) Rituximab; ANDNote: An exception to the requirement for a trial of a systemic therapy can be made if the patient has already tried Enspryng (satralizumab-mwge subcutaneous injection) or Uplizna (inebilizumab-cdon intravenous infusion) for neuromyelitis optica spectrum disorder.

Patients who have already tried Enspryng or Uplizna for neuromyelitis optica spectrum disorder are not required to try another systemic agent.

- iv. Patient has a of at least 1 relapse in the last 12 months or two relapses in the last 2 years; AND
 - v. The medication is being prescribed by or in consultation with a neurologist.
- B) Patient is Currently Receiving Soliris.** Approve for 1 year if the patient meets the following (i, ii, iii, and iv):
- i. Patient is ≥ 18 years of age; AND
 - ii. Neuromyelitis optica spectrum disorder diagnosis was confirmed by a positive blood serum test for anti-aquaporin-4 antibody; AND
 - iii. According to the prescriber, patient has had clinical benefit from the use of Soliris; AND
Note: Examples of clinical benefit include reduction in relapse rate, reduction in symptoms (e.g., pain, fatigue, motor function), and a slowing progression in symptoms.
 - iv. The medication is being prescribed by or in consultation with a neurologist.
- 4. Paroxysmal Nocturnal Hemoglobinuria.** Approve if the patient meets ONE of the following (A or B):
- A) Initial therapy.** Approve for 6 months if the patient meets the following criteria (i, ii, and iii):
- i. Patient is ≥ 18 years of age; AND
 - ii. Paroxysmal nocturnal hemoglobinuria diagnosis was confirmed by peripheral blood flow cytometry results showing the absence or deficiency of glycosylphosphatidylinositol (GPI)-anchored proteins on at least two cell lineages; AND
 - iii. The medication is being prescribed by or in consultation with a hematologist.
- B) Patient is Currently Receiving Soliris.** Approve for 1 year if the patient meets the following (i, ii, and iii):
- i. Patient is ≥ 18 years of age; AND
 - ii. Patient is continuing to derive benefit from Soliris, according to the prescriber; AND
Note: Examples of derived benefit include stabilization of hemoglobin levels, decreased transfusion requirements or transfusion independence, reductions in hemolysis.
 - iii. Medication is prescribed by or in consultation with a hematologist.

CONDITIONS NOT RECOMMENDED FOR APPROVAL

Coverage of Soliris is not recommended in the following situations:

- 1. Concomitant Use with a rituximab product, Enspryng (satralizumab-mwge subcutaneous injection), Ultomiris (ravulizumab intravenous infusion), or Uplizna (inebilizumab-cdon intravenous infusion).** There is no evidence to support combining Soliris with rituximab, Enspryng, Ultomiris, or Uplizna.
- 2. Concomitant Use with Empaveli (pegcetacoplan subcutaneous infusion) > 4 Weeks.** Concurrent use of Soliris with Empaveli is not recommended. However, to reduce the risk of hemolysis from abrupt treatment discontinuation, patients currently receiving Soliris and switching to Empaveli may receive these agents for no more than 4 weeks after starting Empaveli.
- 3. Coverage is not recommended for circumstances not listed in the Recommended Authorization Criteria.** Criteria will be updated as new published data are available.

REFERENCES

1. Soliris® intravenous infusion [prescribing information]. New Haven, CT: Alexion; April 2021.

05/04/2022

© 2022. All Rights Reserved.

This document is confidential and proprietary. Unauthorized use and distribution are prohibited.

2. Campistol JM, Arias M, Ariceta G, et al. An update for atypical haemolytic uraemic syndrome: diagnosis and treatment. A consensus document. *Nefrologia*. 2015;35:421–447.
3. Genetics Home Reference. Atypical hemolytic-uremic syndrome. National Institutes of Health (NIH). Available at: <https://ghr.nlm.nih.gov/condition/atypical-hemolytic-uremic-syndrome#sourcesforpage>. Accessed on April 29, 2022.
4. National Institute of Neurological Disorders and Stroke (NINDS). Myasthenia Gravis Fact Sheet. National Institutes of Health (NIH) Publication No. 17-768. Publication last updated: November 15, 2021. Available at: <https://www.ninds.nih.gov/Disorders/Patient-Caregiver-Education/Fact-Sheets/Myasthenia-Gravis-Fact-Sheet>. Accessed on April 29, 2022.
5. Sanders DB, Wolfe GI, Benatar M, et al. International consensus guidance for management of myasthenia gravis. *Neurology*. 2016;87:419–425.
6. National Organization for Rare Disorders. Neuromyelitis Optica Spectrum Disorder. Available at: <https://rarediseases.org/rare-diseases/neuromyelitis-optica/>. Accessed April 29, 2022.
7. National Institute of Health, U.S. National Library of Medicine. Genetics Home Reference. Neuromyelitis optica. Available at: <https://ghr.nlm.nih.gov/condition/neuromyelitis-optica#genes>. Accessed April 29, 2022.
8. Enspryng™ subcutaneous injection [prescribing information]. South San Francisco, CA: Genentech; August 2020.
9. Uplizna™ intravenous infusion [prescribing information]. Gaithersburg, MD: Viela Bio; July 2021.
10. Bradshaw MJ, Kimbrough D. Neuromyelitis Optica Spectrum Disorders. *Practical Neurology*. 2019;76-84.
11. Siegel Rare Neuroimmune Association. Neuromyelitis Optica Spectrum Disorders. https://wearesrna.org/wp-content/uploads/2018/06/About_NMOSD_2018.pdf. Accessed on April 29, 2022.
12. Hillmen P, Szer J, Weitz I, et al. Pegcetacoplan versus eculizumab in paroxysmal nocturnal hemoglobinuria. *N Engl J Med*. 2021;384(11):1028-1037.
13. Parker CJ. Update on the diagnosis and management of paroxysmal nocturnal hemoglobinuria. *Hematology Am Soc Hematol Edu Program*. 2016;2016(1):208-216.
14. Roth A, Maciejewski J, Nishinura JI, et al. Screening and diagnostic clinical algorithm for paroxysmal nocturnal hemoglobinuria: Expert consensus. *Eur J Haematol*. 2018;101(1):3-11.
15. Empaveli™ subcutaneous infusion [prescribing information]. Waltham, MA: Apellis; August 2021.
16. Ultomiris® intravenous infusion [prescribing information]. Boston, MA: Alexion; April 2022.
17. Narayanaswami P, Sanders DB, Wolfe G, et al. International Consensus Guidance for Management of Myasthenia Gravis: 2020 Update. *Neurology*. 2021 Jan 19;96(3):114-122.